 | |
| Clinical data | |
|---|---|
| Other names | EBCO; Estradiol 3-benzoate 17β-cyclooctenyl ether |
| Routes of administration | By mouth[1] |
| Drug class | Estrogen;Estrogen ester;Estrogen ether |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C33H40O3 |
| Molar mass | 484.680 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estradiol benzoate cyclooctenyl ether (EBCO), orestradiol 3-benzoate 17β-cyclooctenyl ether, is asyntheticestrogen as well asestrogen ester andether – specifically, the C3benzoateester and C17βcyclooctenylether ofestradiol – which was described in the early 1970s and was never marketed.[1][2][3][4] It has been found to have a dramatically prolongedduration of action withoral administration in animals, similarly to the related compoundquinestrol (the 3-cyclopentyl ether ofethinylestradiol).[1][5][6] A single oral dose of EBCO sustained highuterus weights for 3 weeks in rats.[1] This long-lasting activity may be due to storage of EBCO infat.[1] It appears that EBCO isabsorbed satisfactorily from thegastrointestinal tract, at least partially survivesfirst-pass metabolism in theliver andintestines, and is then sequestered into fat, from which it is slowly released and activated into estradiol.[1] In contrast to quinestrol, the oral activity of EBCO is greatly improved when it is delivered in anoil solution as opposed to anaqueous vehicle.[1]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |